At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Fluoxetinedrug
Likely dose
Fluoxetine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
University of Texas Southwestern Medical Center·interventional·Posted Jul 21, 2009·Updated Jun 2, 2020
In Brief
A Phase 2 clinical trial evaluating Fluoxetine for Pulmonary Arterial Hypertension. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartSep 2009
Primary CompletionJun 2011
Study CompletionAug 2011
TodayJul 2026
First PostedJul 21, 2009
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.9 years ago
Interventions
Fluoxetinedrug
Total dose How to take: Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID